The FDA Fast Track Designation is a positive regulatory milestone for Candel Therapeutics, indicating that the FDA recognizes the potential of CAN-2409 to address an unmet medical need in pancreatic cancer treatment. This designation can lead to expedited development and review of the drug, potentially bringing it to market sooner. Investors often view such regulatory advancements as positive indicators of a company's pipeline progress, which can lead to increased investor confidence and a rise in stock price in the short term.